Diffusion and economic consequences of health technologies in prostate cancer care in Sweden, 1991-2002

被引:14
作者
Sennfalt, Karin
Carlsson, Per
Varenhorst, Eberhard
机构
[1] Linkoping Univ, Ctr Med Technol Assessment, Linkoping, Sweden
[2] Linkoping Univ Hosp, Dept Urol, S-58185 Linkoping, Sweden
关键词
prostate cancer; costs; diffusion; health technologies;
D O I
10.1016/j.eururo.2005.12.018
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To describe the diffusion of six main health technologies used for management of prostate cancer, to estimate the economic consequences of technological changes, and to explore factors behind the diffusion. Methods: Data describing the diffusion 1991-2002 were obtained from population-based databases. Costs were obtained from Linkoping University Hospital and Apoteket AB. Factors affecting the diffusion of the technologies were explored. Results: Utilization of technologies with a curative and/or palliative aim has increased over time, except for surgical castration. PSA-tests are used increasingly. The total cost of the study technologies has increased from 20 million euros in 1991 to 65 million euros in 2002. Classification of radical prostatectomy revealed a profile associated with a slow/limited diffusion, while classification of PSA-tests revealed a profile associated with a rapid/extensive diffusion. Conclusions: Several technological changes in the management of prostate cancer have occurred without proven benefits and have contributed to increased costs. There are other factors, besides scientific evidence, that have an impact on the diffusion. Consequently, activities aimed at facilitating an appropriate diffusion of new technologies are needed. The analytical framework used here may be helpful in identifying technologies that are likely to experience inappropriate diffusion and therefore need particular attention. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:1028 / 1034
页数:7
相关论文
共 23 条
[1]  
[Anonymous], 2003, Diffusion of Innovations
[2]   EAU guidelines on prostate cancer [J].
Aus, G ;
Abbou, CC ;
Pacik, D ;
Schmid, HP ;
van Poppel, H ;
Wolff, JM ;
Zattoni, F .
EUROPEAN UROLOGY, 2001, 40 (02) :97-101
[3]   Radical prostatectomy versus watchful waiting in early prostate cancer [J].
Bill-Axelson, A ;
Holmberg, L ;
Ruutu, M ;
Häggman, M ;
Andersson, SO ;
Bratell, S ;
Spångberg, A ;
Busch, C ;
Nordling, S ;
Garmo, H ;
Palmgren, J ;
Adami, HO ;
Norlén, BJ ;
Johansson, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (19) :1977-1984
[4]   The early experiences of a national system for the identification and assessment of emerging health care technologies in Sweden [J].
Carlsson, P ;
Hultin, H ;
Törnwall, J .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1998, 14 (04) :687-694
[5]   THE COST OF PROSTATIC-CANCER IN A DEFINED POPULATION [J].
CARLSSON, P ;
HJERTBERG, H ;
JONSSON, B ;
VARENHORST, E .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1989, 23 (02) :93-96
[6]   Scanning the horizon for emerging health technologies - Conclusions from a European Workshop [J].
Carlsson, P ;
Jorgensen, T .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1998, 14 (04) :695-704
[7]  
CARLSSON P, 1987, SPRIDNING EKONOMISKA
[8]  
Holmberg H, 1998, SCAND J UROL NEPHROL, V32, P195
[9]   Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup [J].
Iversen, P ;
Tyrrell, CJ ;
Kaisary, AV ;
Anderson, JB ;
Van Poppel, H ;
Tammela, TLJ ;
Chamberlain, M ;
Carroll, K ;
Melezinek, I .
JOURNAL OF UROLOGY, 2000, 164 (05) :1579-1582
[10]   Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year. median followup from the Scandinavian prostate cancer group study number 6 [J].
Iversen, P ;
Johansson, JE ;
Lodding, P ;
Lukkarinen, O ;
Lundmo, P ;
Klarskov, P ;
Tammela, TLJ ;
Tasdemir, I ;
Morris, T ;
Carroll, K .
JOURNAL OF UROLOGY, 2004, 172 (05) :1871-1876